A new AHRQ research review found no or limited evidence that screening, monitoring, and treating adults with early-stage chronic kidney disease was beneficial to patients.
The condition affects more than 44% of US adults over the age of 70.
The review examined screening, monitoring, and treatment of adults in stage 1, 2 or 3 of the five stages of chronic kidney disease.
Select to read Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment by clicking here.
[Source: AHRQ]
 |
 |
 |
 |
CLP is the only magazine that focuses exclusively on products and technology for the clinical lab industry. Every month, CLP's editorial provides 45,000 pathologists, lab managers, administrators and technologists with comprehensive coverage of new products and technology.
RSS